Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;11(7):990-1000.
doi: 10.34172/ijhpm.2020.243. Epub 2020 Dec 14.

Evaluation of Pharmacovigilance System in Iran

Malahat Khalili  1 , Hamid Sharifi  1 , Bita Mesgarpour  2 , Mehrnaz Kheirandish  3 , Sten Olsson  4   5 , Naghmeh Javidnikou  1 , Ali Akbar Haghdoost  1
Affiliations

Evaluation of Pharmacovigilance System in Iran

Malahat Khalili et al. Int J Health Policy Manag. .

Abstract

Background: Evaluating a pharmacovigilance system helps identify its deficiencies and could facilitate measures to remedy and improve the quantity and quality of adverse drug reaction (ADR) reports and other opportunities for pharmacovigilance systems strengthening. This study aimed to evaluate the status of pharmacovigilance in Iran using the World Health Organization (WHO) pharmacovigilance indicators with the prospect of identifying the gaps and areas for improvement.

Methods: This study was conducted in 2 parts. The first part included a secondary analysis of the national data obtained from the Iranian National Pharmacovigilance Center (PVC) using a structured data collection form based on WHO core pharmacovigilance indicators. In the second part, a 3-month prospective study was carried out to investigate 2 outcome indicators, ie, length of stay and costs of medicine-related hospitalization in all patients of 2 main referral hospitals in the southeast and north of Iran.

Results: Iran has a PVC with national policy, trained staff, and a statutory budget. In 2017, the number of ADR reports was 15.0 per 100 000 population, and 262 signals were detected during the preceding 5 years. The average length of stay and costs of medicine-related hospitalization were 5 days and US$817.2 in Afzalipour hospital and 6.6 days and US$306.7 in Razi hospital, respectively. The status of pharmacovigilance in the Iranian public health programs (PHPs) is unknown, and most of the indicators could not be assessed.

Conclusion: A robust pharmacovigilance system is a pivotal part of the overall medicines regulatory system. The Iranian pharmacovigilance system has relatively the proper structural condition. Though the underreporting of ADRs, especially medicine-related deaths, is an important issue, and some indicators' status was unclear. The Iranian pharmacovigilance program requires a higher prioritization, particularly in the PHPs, a greater allocation of resources, and cross-sectoral cooperation to bolster and achieve the pharmacovigilance objectives.

Keywords: Adverse Drug Reaction; Iran; Pharmacoepidemiology; Pharmacovigilance.

PubMed Disclaimer

References

    1. Linnér L, Eriksson I, Persson M, Wettermark B. Forecasting drug utilization and expenditure: ten years of experience in Stockholm. BMC Health Serv Res. 2020;20(1):410. doi: 10.1186/s12913-020-05170-0. - DOI - PMC - PubMed
    1. Qato DM. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey. Int J Pharm Pract. 2018;26(3):210–221. doi: 10.1111/ijpp.12372. - DOI - PubMed
    1. Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso. Drug Saf. 2013;36(5):349–358. doi: 10.1007/s40264-013-0043-9. - DOI - PubMed
    1. Amin S, Mishra V, Mira D, Rajesh S. Pattern of adverse drug reactions and its potential impact on drug resistant tuberculosis patients at a tertiary care teaching hospital in Western India. Clin J Pharmacol Pharmacother. 2018;1(1):1004.
    1. World Health Organization (WHO). Minimum Requirements for A Functional Pharmacovigilance System. https://apps.who.int/medicinedocs/en/m/abstract/Js23393en/. Published 2010.

MeSH terms